Form 8-K - Current report:
SEC Accession No. 0001193125-26-278642
Filing Date
2026-06-23
Accepted
2026-06-23 10:09:39
Documents
9
Period of Report
2026-06-17
Items
Item 5.07: Submission of Matters to a Vote of Security Holders

Document Format Files

Seq Description Document Type Size
1 8-K inkt-20260617.htm   iXBRL 8-K 56367
  Complete submission text file 0001193125-26-278642.txt   165780

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT inkt-20260617.xsd EX-101.SCH 25843
12 EXTRACTED XBRL INSTANCE DOCUMENT inkt-20260617_htm.xml XML 4885
Mailing Address 149 FIFTH AVENUE SUITE 500 NEW YORK NY 10010
Business Address 149 FIFTH AVENUE SUITE 500 NEW YORK NY 10010 212-994-8250
MiNK Therapeutics, Inc. (Filer) CIK: 0001840229 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40908 | Film No.: 261109403
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)